Viking Therapeutics will launch a longship into phase 3 for the obesity drug VK2735 sooner than expected, with a clinical program expected to top $300 million.

After reaching out to more than 200 companies to partner a Tourette syndrome therapy that showed the ability to beat standard of care last year, Asarina Pharma has come up empty and will fold.

Sage Therapeutics and Biogen have extended the pharma industry’s multi-decade essential tremor losing streak. Three years after tolerability overshadowed efficacy, the partners have given up on SAGE-324 in the indication after failing to reduce tremors in a phase 2 trial designed to address their earlier problems.

The computer-powered molecule designer Insilico Medicine has been no stranger to generative AI—indeed, it was demonstrating that its networked methods could deliver gains in drug discovery well before programs like ChatGPT entered the international conversation—but now the company is taking things a step further with a series of initiatives that aim to make good on AI’s promises for the life sciences industry.

Actuate’s upcoming IPO may be on the smaller side in comparison to its biotech peers that have publicly listed this year, but that hasn’t stopped the cancer-focused company from continuing to tweak its offering.

Pinetree Therapeutics will help AstraZeneca plant some trees in its pipeline with a new pact to develop a preclinical EGFR degrader worth $45 million upfront for the small biotech.

Revenue for clinical research services company IQVIA was boosted by 2.3% in the second quarter compared to the prior-year period, thanks to better-than-expected performance from the company’s technology and analytics solutions offerings.

Tulavi Therapeutics has received a de novo clearance from the FDA for a surgical kit designed to help reduce long-term phantom limb pains among people who have had an amputation.

Flagship Pioneering has thrown $50 million behind a push to create synthetic proteins that overcome the limitations of natural biologics. The money will support Abiologics, a biotech that has grown out of three years of work at Flagship to create a platform capable of birthing the new modality.

GE HealthCare will spend about $51 million in cash to acquire artificial intelligence assets from Intelligent Ultrasound Group, with tech that provides real-time support to clinicians during OB/GYN exams.